Dual inhibition of IL-17A and IL-17F in psoriatic disease.

The difference between placebo group and bimekizumab 320 mg group in ACR50 response at week 12 was very close to statistical significance ( p = 0.051); the ACR50 responses at week 12 with all other bimekizumab doses were significantly superior than placebo, albeit with nominal p values: bimekizumab 16 mg OR 4.2, 95% CI 1.1–15.2, p = 0·032; bimekizumab 160 mg OR 8.1, 95% CI 2.3–28.7, p = 0.0012; bimekizumab 160 mg with loading dose OR

also in 143 other papers